The Medicines Company (NASDAQ:MDCO) insider Fredric N. Eshelman bought 200,000 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $26.56 per share, for a total transaction of $5,312,000.00. Following the purchase, the insider now owns 1,028,383 shares of the company’s stock, valued at $27,313,852.48. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of The Medicines Company (MDCO) opened at $26.00 on Tuesday. The company has a debt-to-equity ratio of 3.42, a current ratio of 2.31 and a quick ratio of 1.79. The Medicines Company has a 52 week low of $25.40 and a 52 week high of $55.95.

The Medicines (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The firm had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The company’s quarterly revenue was down 55.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.64) earnings per share. analysts forecast that The Medicines Company will post -8.86 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of MDCO. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of The Medicines by 10.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after purchasing an additional 264 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of The Medicines during the third quarter worth approximately $171,000. First Mercantile Trust Co. lifted its position in shares of The Medicines by 2.5% during the second quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after purchasing an additional 114 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of The Medicines during the third quarter worth approximately $198,000. Finally, Bluefin Trading LLC acquired a new position in shares of The Medicines during the second quarter worth approximately $214,000.

A number of analysts recently weighed in on the stock. Citigroup raised shares of The Medicines from a “sell” rating to an “outperform” rating in a research note on Thursday, November 30th. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the company a “hold” rating in a research note on Thursday, October 26th. Jefferies Group reaffirmed a “buy” rating and set a $54.00 price objective on shares of The Medicines in a research note on Thursday, October 26th. Chardan Capital reaffirmed a “buy” rating and set a $85.00 price objective on shares of The Medicines in a research note on Wednesday, September 20th. Finally, ValuEngine raised shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The Medicines presently has an average rating of “Buy” and a consensus target price of $53.67.

ILLEGAL ACTIVITY NOTICE: “The Medicines Company (MDCO) Insider Fredric N. Eshelman Buys 200,000 Shares” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/the-medicines-company-mdco-insider-fredric-n-eshelman-buys-200000-shares/1758628.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.